Influence polymorphism of genes interleukin-10 (1082G/A; rs1800896) and tumor necrosis factor-α (308G/A; rs1800629) on risks of developing adverse clinical forms of community-acquired pneumonia in young men

The influence of the structural polymorphism of the interleukin-10 genes (1082G/A; rs1800896) and tumor necrosis factor-α (308G/A; rs1800629) on the risk of adverse clinical forms of community-acquired pneumonia in young men has been evaluated. In patients with community-acquired pneumonia in young men, the GG genotype of the gene for interleukin-10 (1082G/A; rs1800896) and the AA and AG genotypes of the tumor necrosis factor-α gene (308G/A; rs1800629) have been found to be associated with a severe and prolonged course of this diseases. AA and AG genotypes of the tumor necrosis factor-α gene (308G/A; rs1800629) are associated with the complicated course of community-acquired pneumonia in young people. It was revealed that in young men, in the presence of the GG genotype of the interleukin-10 gene (1082G/A; rs1800896), the relative risk of developing severe disease increases by 3,2 times and the risk of developing long-term community- acquired pneumonia increases by 2,7 times. If young patients suffering from community-acquired pneumonia, AA or AG, have the genotype of the tumor necrosis factor-α gene (308G/A; rs1800629), the relative risk of developing severe course increases by 3,3 times, prolonged course - by 2,6 times, and complicated course - 1,9 times. The results of the study should be used in the diagnosis of community-acquired pneumonia in order to predict the development of adverse clinical forms. Interleukin-10 gene polymorphism (1082G/A; rs1800896) and tumor necrosis factor-α (308G/A; rs1800629) are individual typological features of a person, the verification of which is relevant for use in the diagnosis of community-acquired pneumonia in young people to predict development adverse clinical forms of the disease.

community-acquired pneumonia, young age, gene polymorphism, interleukin-10, tumor necrosis factor-α, diagnosis, risk assessment, prognosis of the clinical course